Progressive Q4 Sales $12.89B Beat $12.35B Estimate

Progressive (NYSE:PGR) reported quarterly sales of $12.89 billion which beat the analyst consensus estimate of $12.35 billion by 4.39 percent. This is a 11.13 percent increase over sales of $11.60 billion the same

byBenzinga Newsdesk

January 25, 2023

1 minute read

Citigroup Maintains Buy on Amazon.com, Raises Price Target to $185

By Benzinga Newsdesk

Today, 4:42 AM

Citigroup analyst Ronald Josey maintains Amazon.com (NASDAQ:AMZN) with a Buy and raises the price target from $180 to $185.

AMZN

PHX Minerals Q1 EPS $0.09 Misses $0.15 Estimate, Sales $18.27M Beat $15.57M Estimate

By Happy Mohamed

Today, 4:42 AM

PHX Minerals (NYSE: PHX) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.15 by 40 percent. This is a 55 percent decrease over earnings of $0.20 per share from the same period last year.

PHX

Earnings

Recap: CarGurus Q2 Earnings

By Benzinga Insights

Today, 4:42 AM

Shares of CarGurus (NASDAQ:CARG) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 115.79% over the past year to $0.41, which beat the estimate of $0.21.

CARG

Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials

By Lara Goldstein

Today, 4:42 AM

Psycheceutical Bioscience (OTCPK: BWVI) is advancing its proprietary ketamine topical formulation into clinical studies. The life sciences company has partnered with Australian-based contract research organization iNGENū Pty Ltd.

BWVI

Progressive Q4 Sales $12.89B Beat $12.35B Estimate

Related Posts

Citigroup Maintains Buy on Amazon.com, Raises Price Target to $185

PHX Minerals Q1 EPS $0.09 Misses $0.15 Estimate, Sales $18.27M Beat $15.57M Estimate

Recap: CarGurus Q2 Earnings

Novel Ketamine Topical Cream To Treat PTSD Gets First In-Human Trials